Back to Search
Start Over
Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data
- Source :
- Journal of Clinical Oncology. 34:7520-7520
- Publication Year :
- 2016
- Publisher :
- American Society of Clinical Oncology (ASCO), 2016.
-
Abstract
- 7520Background: Ibrutinib (ibr) is the first-in-class once daily Bruton’s tyrosine kinase inhibitor FDA approved for patients (pts) with CLL with ≥ 1 prior therapy. We evaluated outcomes with ibr b...
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
business.industry
medicine.drug_class
Line of therapy
Tyrosine-kinase inhibitor
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Prior Therapy
chemistry
030220 oncology & carcinogenesis
Internal medicine
Ibrutinib
medicine
In patient
Once daily
business
030215 immunology
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 34
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........a0960342d2841da0f1854c6abbce0216